Ascendis Pharma A/S (ASND)
Stock Price:
$141.00 USD
0.51 (0.36%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
6.77B |
| Revenue (ttm) |
15.79M |
| Net Income (ttm) |
-257.40M |
| Shares Out |
53.17M |
| EPS (ttm) |
-3.87 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$141.00 |
| Previous Close |
$140.49 |
| Change ($) |
0.51 |
| Change (%) |
0.36% |
| Day's Open |
141.00 |
| Day's Range |
139.35 - 142.49 |
| Day's Volume |
82,715 |
| 52-Week Range |
90.06 - 158.93 |
More Stats
| Market Cap |
6.77B |
| Enterprise Value |
6.10B |
| Earnings Date (est) |
Aug 26, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
53.17M |
| Float |
39.92M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-3.87 |
| FCF / Share |
-4.60 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.91M |
| Short Ratio |
5.82 |
| Short % of Float |
n/a |
| Beta |
0.90 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
428.46 |
| PB Ratio |
12.01 |
| Revenue |
15.79M |
| Operating Income |
-267.68M |
| Net Income |
-257.40M |
| Free Cash Flow |
-213.81M |
| Net Cash |
662.92M |
| Net Cash / Share |
13.81 |
| Gross Margin |
100.00% |
| Operating Margin |
-1,695.10% |
| Profit Margin |
-1,630.00% |
| FCF Margin |
-1,353.98% |
| ROA |
-22.02% |
| ROE |
-35.99% |
| ROIC |
n/a |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (11)
| Buy |
11 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$184.60*
(30.92% upside)
Low
161
Current: $141.00
High
224
Target: 184.60
*Average 12-month USD price target from 11 stock analysts.
Financial Performance
Financial numbers in millions EUR.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 13.38 | 10.58 | 1.53 | 4.61 | 8.12 | 13.98 | 20.41 | 15.58 |
| Revenue Growth | 26.41% | 591.57% | -66.78% | -43.26% | -41.94% | -31.48% | 30.96% | - |
| Gross Profit | 13.38 | 10.58 | 1.53 | 4.61 | 8.12 | 13.98 | 20.41 | 15.58 |
| Operating Income | -227 | -155 | -112 | -72.92 | -41.83 | -11.99 | 5.28 | 1.51 |
| Net Income | -218 | -130 | -124 | -68.51 | -32.92 | -9.66 | 4.08 | 1.25 |
| Shares Outstanding | 46.51 | 41.09 | 33.63 | 26.56 | 23.77 | 11.41 | 10.80 | 8.41 |
| Earnings Per Share | -4.69 | -3.17 | -3.68 | -2.58 | -1.39 | -0.85 | 0.32 | 0.14 |
| EPS Growth | - | - | - | - | - | - | 128.57% | - |
| Operating Cash Flow | -176 | -139 | -95.10 | -60.18 | -43.47 | -18.40 | 6.31 | -0.65 |
| Capital Expenditures | -5.16 | -2.65 | -0.94 | -0.67 | -1.04 | -0.41 | -1.20 | -0.29 |
| Free Cash Flow | -181 | -141 | -96.04 | -60.85 | -44.51 | -18.81 | 5.12 | -0.94 |
| Cash & Equivalents | 598 | 278 | 195 | 180 | 120 | 50.17 | 19.43 | 14.54 |
| Total Debt | 36.62 | - | - | - | - | - | - | 0.21 |
| Net Cash / Debt | 561 | 278 | 195 | 180 | 120 | 50.17 | 19.43 | 14.32 |
| Assets | 677 | 319 | 211 | 190 | 132 | 58.67 | 26.70 | 25.41 |
| Liabilities | 79.62 | 38.92 | 23.77 | 13.46 | 11.45 | 12.86 | 20.40 | 23.85 |
| Book Value | 597 | 280 | 187 | 177 | 120 | 45.81 | 6.30 | 1.56 |
Numbers in millions EUR, except per-share numbers.
Company Details
| Full Name |
Ascendis Pharma A/S |
| Country |
Denmark |
| Employees |
330 |
| CEO |
Jan Møller Mikkelsen |
Stock Information
| Ticker Symbol |
ASND |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ASND |
| IPO Date |
January 28, 2015 |
Description
Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon technologies for the treatment of diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.